Literature DB >> 27093081

The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.

Weilan Ye1.   

Abstract

Formation of new blood vessels in tumors, a process termed tumor angiogenesis, is a crucial step during oncogenic progression. Blocking tumor angiogenesis is therefore expected to have a profound impact on tumor growth. It took several decades of collective efforts to translate this intriguing idea into tangible clinical benefit. Today, anti-angiogenesis agents represent standard-of-care therapies for multiple types of cancers, and the clinical experience has taught us many lessons about the concept and application of anti-angiogenesis. This Perspective is an attempt to summarize these lessons and how they can be leveraged to improve anti-angiogenesis therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27093081     DOI: 10.1016/j.devcel.2016.03.015

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  38 in total

Review 1.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

2.  [68Ga]RGD Versus [18F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide.

Authors:  Claire Provost; Laura Rozenblum-Beddok; Valérie Nataf; Fatiha Merabtene; Aurélie Prignon; Jean-Noël Talbot
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

3.  Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.

Authors:  Shweta Sharma; Aman P Mann; Tarmo Mölder; Venkata Ramana Kotamraju; Robert Mattrey; Tambet Teesalu; Erkki Ruoslahti
Journal:  J Control Release       Date:  2017-10-13       Impact factor: 9.776

Review 4.  Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression.

Authors:  Li Yang; P Charles Lin
Journal:  Semin Cancer Biol       Date:  2017-08-03       Impact factor: 15.707

Review 5.  Modulation of VEGF receptor 2 signaling by protein phosphatases.

Authors:  Federico Corti; Michael Simons
Journal:  Pharmacol Res       Date:  2016-11-23       Impact factor: 7.658

6.  Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH.

Authors:  Divyabharathy Tsiros; Casey E Sheehy; Surenna Pecchia; Matthew A Nugent
Journal:  J Biol Chem       Date:  2019-10-10       Impact factor: 5.157

Review 7.  The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis.

Authors:  Abdulrahman Alwhaibi; Arti Verma; Mir S Adil; Payaningal R Somanath
Journal:  Pharmacol Res       Date:  2019-05-09       Impact factor: 7.658

8.  Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis.

Authors:  Ashraf Ul Kabir; Tae-Jin Lee; Hua Pan; Jeffrey C Berry; Karen Krchma; Jun Wu; Fang Liu; Hee-Kyoung Kang; Kristina Hinman; Lihua Yang; Samantha Hamilton; Qingyu Zhou; Deborah J Veis; Robert P Mecham; Samuel A Wickline; Mark J Miller; Kyunghee Choi
Journal:  JCI Insight       Date:  2018-04-19

9.  A mathematical model of angiogenesis and tumor growth: analysis and application in anti-angiogenesis therapy.

Authors:  Xiaoming Zheng; Mohye Sweidan
Journal:  J Math Biol       Date:  2018-07-17       Impact factor: 2.259

10.  Robust Tracing and Visualization of Heterogeneous Microvascular Networks.

Authors:  Pavel A Govyadinov; Tasha Womack; Jason L Eriksen; Guoning Chen; David Mayerich
Journal:  IEEE Trans Vis Comput Graph       Date:  2018-03-27       Impact factor: 4.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.